Fig. 2
BRAF-activated WT1 is highly expressed in thyroid cancer patients and predicts poor prognosis. A The differentially expressed genes between thyroid cancer tissues and normal tissues in the TCGA database. B The common regulators among the prognostic genes and DEGs in thyroid cancer patients carrying BRAF-MT and BRAF WT. C The importance of 67 common genes in thyroid cancer patients. D The expression level of WT1 in non-tumor samples compared with that in THCA samples. E The mRNA level of WT1 in THCA samples with or without BRAF mutation. F The protein level of WT1 in non-tumor tissues and THCA tumor tissues. G The protein expression of WT1 in THCA patients carrying BRAF WT or BRAF MT. H, I Quantification of immunohistochemistry data of WT1 expression in different groups. J, K KM plot and ROC curve showing the prognostic value of WT1 in thyroid cancer patients (*P < 0.05, **P < 0.01)